Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (5): 482-486.doi: 10.3969/j.issn.1000-6621.2021.05.013
• Original Articles • Previous Articles Next Articles
WANG Lu*, XUE Zhong-tan, WANG Yu-feng, SHANG Yuan-yuan, REN Wei-cong, YAO Cong, GAO Fei(), PANG Yu(
)
Received:
2021-01-30
Online:
2021-05-10
Published:
2021-04-30
Contact:
GAO Fei,PANG Yu
E-mail:gaofeiwho@163.com;pangyupound@163.com
WANG Lu, XUE Zhong-tan, WANG Yu-feng, SHANG Yuan-yuan, REN Wei-cong, YAO Cong, GAO Fei, PANG Yu. A study of dynamic monitoring of drug sensitivity of Mycobacterium tuberculosis to bedaquiline and the mechanism of drug resistance[J]. Chinese Journal of Antituberculosis, 2021, 43(5): 482-486. doi: 10.3969/j.issn.1000-6621.2021.05.013
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.05.013
药品 | 耐药临界MIC(μg/ml) |
---|---|
贝达喹啉(bedaquiline,Bdq) | 0.25 |
利福平(rifampicin,RFP) | 1 |
异烟肼(isoniazid,INH) | 0.25 |
利奈唑胺(linezolid,Lzd) | 1 |
氯法齐明(clofazimine,Cfz) | 0.5 |
左氧氟沙星(levofloxacin,Lfx) | 2 |
氧氟沙星(ofloxacin,Ofx) | 2 |
莫西沙星(moxifloxacin,Mfx) | 0.5 |
卷曲霉素(capreomycin,Cm) | 2 |
卡那霉素(kanamycin,Km) | 4 |
阿米卡星(amikacin,Am) | 1 |
乙胺丁醇(ethambutol,EMB) | 4 |
患者编号 | atpE | Rv0678 | pepQ | Rv1979c |
---|---|---|---|---|
原发耐药 | ||||
SY0017 | 野生型 | G326C(CG-/CC-);G398A(AGC/AAC) | 野生型 | 野生型 |
SY0036 | 野生型 | C257T(GCC/GTC) | 野生型 | 野生型 |
CD0004 | 野生型 | G328-(GCA/-CA) | 野生型 | 野生型 |
CD0006 | 野生型 | G253T(GTC/TTC) | 野生型 | 野生型 |
获得性耐药 | ||||
SY0009 | 野生型 | G363-(GGG/GG-) | 野生型 | G730A(GAA/AAA) |
SY0011 | 野生型 | 144~145之间插入C;G393C(CAG/CAC); G401A(CGA/CAA) | 野生型 | 野生型 |
SY0016 | 野生型 | 144~145之间插入C | 野生型 | 野生型 |
敏感性降低 | ||||
ZZ0005 | 野生型 | G287A(CGG/CAG) | 野生型 | 野生型 |
ZZ0018 | 野生型 | 139~140之间插入G | 野生型 | 野生型 |
HL0023 | 野生型 | 野生型 | 野生型 | T789G(GTT/GTG) |
[1] | 厉娟, 聂理会, 唐神结. 贝达喹啉抗结核作用及其研究进展. 中华医学杂志, 2015,95(16):1275-1277. doi: 10.3760/cma.j.issn.0376-2491.2015.16.023. |
[2] | 姚岚, 唐神结. WHO 2014年版《耐药结核病规划管理指南伙伴手册》解读之四(贝达喹啉在治疗耐多药结核病中的应用). 中国防痨杂志, 2015,37(5):534-536. doi: 10.3969/j.issn.1000-6621.2015.05.014. |
[3] |
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005,307(5707):223-227. doi: 10.1126/science.1106753.
doi: 10.1126/science.1106753 URL |
[4] |
Kaniga K, Aono A, Borroni E, et al. Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study. J Clin Microbiol, 2020,58(4):e01677-19. doi: 10.1128/JCM.01677-19.
URL pmid: 31969421 |
[5] |
Veziris N, Bernard C, Guglielmetti L, et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors. Eur Respir J, 2017,49(3):1601719. doi: 10.1183/13993003.01719-2016.
doi: 10.1183/13993003.01719-2016 URL pmid: 28182568 |
[6] |
Bloemberg GV, Keller PM, Stucki D, et al. Acquired Resis-tance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med, 2015,373(20):1986-1988. doi: 10.1056/NEJMc1505196.
URL pmid: 26559594 |
[7] |
Nguyen TVA, Anthony RM, Bañuls AL, et al. Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention. Clin Infect Dis, 2018,66(10):1625-1630. doi: 10.1093/cid/cix992.
URL pmid: 29126225 |
[8] |
Ismail NA, Omar SV, Joseph L, et al. Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine, 2018,28:136-142. doi: 10.1016/j.ebiom.2018.01.005.
doi: 10.1016/j.ebiom.2018.01.005 URL pmid: 29337135 |
[9] |
Pontali E, Sotgiu G, D’Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J, 2016,47(2):394-402. doi: 10.1183/13993003.01891-2015.
doi: 10.1183/13993003.01891-2015 URL pmid: 26828052 |
[10] |
Peretokina IV, Krylova LY, Antonova OV, et al. Reduced susceptibility and resistance to bedaquiline in clinical M.tuberculosis isolates. J Infect, 2020,80(5):527-535. doi: 10.1016/j.jinf.2020.01.007.
doi: 10.1016/j.jinf.2020.01.007 URL pmid: 31981638 |
[11] |
Xu J, Wang B, Hu M, et al. Primary Clofazimine and Beda-quiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother, 2017,61(6):e00239-17. doi: 10.1128/AAC.00239-17.
doi: 10.1128/AAC.00239-17 URL pmid: 28320727 |
[12] |
Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2014,58(5):2979-2981. doi: 10.1128/AAC.00037-14.
URL pmid: 24590481 |
[13] |
Almeida D, Ioerger T, Tyagi S, et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2016,60(8):4590-4599. doi: 10.1128/AAC.00753-16.
URL pmid: 27185800 |
[14] | World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. |
[15] | 中华医学会结核病学分会. 中国耐多药和利福平耐药结核病治疗专家共识(2019年版). 中华结核和呼吸杂志, 2019,42(10):733-749. doi: 10.3760/cma.j.issn.1001-0939.2019.10.006. |
[16] |
Somoskovi A, Bruderer V, Hömke R, et al. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J, 2015,45(2):554-557. doi: 10.1183/09031936.00142914.
URL pmid: 25359333 |
[1] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[2] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[3] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[4] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[5] | Huang Misun, Wu Yaning, Li Guilian, Liu Haican. Research advances of Mycobacterium tuberculosis enrichment technology [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 369-373. |
[6] | Yang Ziyi, Chen Suting. Research progress on bedaquiline resistance and drug resistance diagnosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 374-379. |
[7] | Zhang Chao, Yu Xia, Huang Hairong, Liu Wei, Liu Tao. Evaluation of the in vitro antimicrobial effects of sevoflurane on Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 158-163. |
[8] | Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168. |
[9] | Xu Zian, Pu Feifei, Feng Jing, Xia Ping. Research progress of high-throughput sequencing technology in the diagnosis and treatment of osteoarticular tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 224-230. |
[10] | Liu Ruihua, Sarina , Wang Furong. Interaction between lung cancer and tuberculosis in disease development and progression [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 102-111. |
[11] | Chen Jifei, Huang Lihua, Luo Lanbo, Sui Wenxian, Pang Yu, Liu Aimei. Evaluation the efficacy of tongue swab-based PCR fluorescence probe method for pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 51-60. |
[12] | Lu Hailin, Wang Wenfei, Tao Wenhui, Lin Peicong, Chen Xinchun, Deng Guofang, Xie Shuixiang. Oleic acid upregulates the expression of perilipin 2 enhancing macrophage clearance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 72-76. |
[13] | Geng Zimei, Wang Chaohong, Long Sibo, Zheng Maike, Shi Yiheng, Sun Yong, Zhao Yan, Wang Guirong. Analysis of bacteriological positivity and rifampicin resistance in patients with severe pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1050-1055. |
[14] | Chen Shuangshuang, Tian Lili, Wang Nenhan, Yang Xinyu, Zhao Yanfeng, Li Chuanyou, Dai Xiaowei. Analysis of in vitro antibacterial effects of 17 antibiotics against rapidly growing mycobacteria in the Beijing area [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1056-1062. |
[15] | Wang Yilin, Wu Xiao, Pang Yu, Li Shanshan. Immunomodulatory effect of orelabrutinib in host macrophages infected with mycobacterium [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1063-1068. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||